Mark Kotter, bit.bio CEO
November 8, 2023 03:00 AM EST
Startups
Cell/Gene Tx

Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Ayisha Sharma

News Reporter

Bit.bio has lift­ed the cur­tain on its ear­ly pipeline of re­gen­er­a­tive med­i­cine can­di­dates made us­ing its cell pro­gram­ming tech­nol­o­gy, which is in­tend­ed to de­ter­min­is­ti­cal­ly trans­form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times